Paper37736699
Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Xia Z and 8 others. Infect Dis Poverty, 2023. Cited by 29 papers, by iCite.
Cite this record
ConductScience Library. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Papers, record 37736699. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37736699
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Hepatitis B | Major topic |
| Humans | |
| Immune Checkpoint Inhibitors | |
| Retrospective Studies | |
| Hepatitis B virus |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 320.6750.2022.20-24 | Wu Jieping Medical Foundation | PubMed | ||
| NCC201919B03 | National Cancer Center Pandeng Foundation | PubMed |
Source PubMed
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36221140 | Impact of the national hepatitis B immunization program in China: a modeling study. | Infect Dis Poverty | 2022 | https://conductscience.org/library/papers/36221140 | PubMed |
| 2 | 35297794 | Comparative Safety, Efficacy and Survival Outcome of Anti-PD-1 Immunotherapy in Colorectal Cancer Patients With vs Without Hepatitis B Virus Infection: A Multicenter Cohort Study. | Clin Transl Gastroenterol | 2022 | https://conductscience.org/library/papers/35297794 | PubMed |
| 3 | 35421228 | Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35421228 | PubMed |
| 4 | 33139266 | Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33139266 | PubMed |
| 5 | 34371536 | [Effects of programmed death receptor-1 antibody in patients with hepatitis B-associated liver cancer]. | Zhonghua Gan Zang Bing Za Zhi | 2021 | https://conductscience.org/library/papers/34371536 | PubMed |
| 6 | 28241095 | Immune checkpoint inhibitors in challenging populations. | Cancer | 2017 | https://conductscience.org/library/papers/28241095 | PubMed |
| 7 | 35601125 | Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection. | JGH Open | 2022 | https://conductscience.org/library/papers/35601125 | PubMed |
| 8 | 35611266 | Updated Survival and Secondary Safety and Efficacy Analyses From CA 209-678: A Phase 2, Open-Label, Single-Center Study of Y90-Radioembolization in Combination With Nivolumab in Asian Patients With Advanced Hepatocellular Carcinoma. | Gastroenterol Hepatol (N Y) | 2021 | https://conductscience.org/library/papers/35611266 | PubMed |
| 9 | 36580258 | Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors. | Hepatol Int | 2023 | https://conductscience.org/library/papers/36580258 | PubMed |
| 10 | 32423643 | Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. | Lung Cancer | 2020 | https://conductscience.org/library/papers/32423643 | PubMed |
| 11 | 34430357 | Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy. | Transl Lung Cancer Res | 2021 | https://conductscience.org/library/papers/34430357 | PubMed |
| 12 | 36589726 | Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition). | Liver Cancer | 2022 | https://conductscience.org/library/papers/36589726 | PubMed |
| 13 | 2230000 | Spontaneous reactivation in chronic hepatitis B: patterns and natural history. | J Clin Gastroenterol | 1990 | https://conductscience.org/library/papers/2230000 | PubMed |
| 14 | 33241036 | Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. | Ann Transl Med | 2020 | https://conductscience.org/library/papers/33241036 | PubMed |
| 15 | 33560651 | Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. | Am J Gastroenterol | 2021 | https://conductscience.org/library/papers/33560651 | PubMed |
| 16 | 34918361 | Risk of HBV reactivation during therapies for HCC: A systematic review. | Hepatology | 2022 | https://conductscience.org/library/papers/34918361 | PubMed |
| 17 | 31753012 | Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/31753012 | PubMed |
| 18 | 19621070 | The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. | PLoS Med | 2009 | https://conductscience.org/library/papers/19621070 | PubMed |
| 19 | 28434648 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. | Lancet | 2017 | https://conductscience.org/library/papers/28434648 | PubMed |
| 20 | 29875066 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. | Lancet Oncol | 2018 | https://conductscience.org/library/papers/29875066 | PubMed |
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42829048 | Combining antiviral therapy with cancer treatment in HBV-associated HCC: A translational approach. | Virus Res | 2026 | https://conductscience.org/library/papers/42829048 | PubMed |
| 42792706 | Hepatic and Pancreatobiliary Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Multidisciplinary Approach. | Biomedicines | 2026 | https://conductscience.org/library/papers/42792706 | PubMed |
| 42757131 | Regulatory T-cell remodeling across the HBV infection-cirrhosis continuum. | Front Immunol | 2026 | https://conductscience.org/library/papers/42757131 | PubMed |
| 42614304 | Immune checkpoint inhibitors in infectious diseases: therapeutic reinvigoration, immunopathology, and precision targeting. | Front Immunol | 2026 | https://conductscience.org/library/papers/42614304 | PubMed |
| 42233029 | Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease. | Front Immunol | 2026 | https://conductscience.org/library/papers/42233029 | PubMed |
| 42176073 | Breakthroughs in HBV-related HCC Therapy: The Unmatched Potential of Immune Checkpoint Inhibitors. | Curr Treat Options Oncol | 2026 | https://conductscience.org/library/papers/42176073 | PubMed |
| 42125666 | Virus-driven remodeling of the immune microenvironment and response to immune checkpoint inhibitors: the infection- immunity-cancer crosstalk. | Front Immunol | 2026 | https://conductscience.org/library/papers/42125666 | PubMed |
| 42112392 | Hepatitis B virus infection and outcomes of TACE plus lenvatinib and PD-1 inhibitor therapy in unresectable hepatocellular carcinoma: a real-world propensity score-matched study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42112392 | PubMed |
| 41898402 | Across the Social Network of the Gut: Bacterial, Fungal, and Viral Determinants of Checkpoint Inhibitor Efficacy and Toxicity. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41898402 | PubMed |
| 41784912 | Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances. | Clin Exp Med | 2026 | https://conductscience.org/library/papers/41784912 | PubMed |
| 41743730 | HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical management. | Front Immunol | 2026 | https://conductscience.org/library/papers/41743730 | PubMed |
| 41566859 | Letter: Using Anti-HBs Titers to Tailor HBV Reactivation Monitoring in Patients With Solid Tumours-Authors' Reply. | Aliment Pharmacol Ther | 2026 | https://conductscience.org/library/papers/41566859 | PubMed |
| 41479885 | Beyond monoclonal antibodies: constraints and the case for alternative PD-1/PD-L1-targeting formats. | Front Immunol | 2025 | https://conductscience.org/library/papers/41479885 | PubMed |
| 41183666 | Antineoplastic agents-associated hepatitis B virus reactivation: Research progress and molecular mechanisms. | Virus Res | 2025 | https://conductscience.org/library/papers/41183666 | PubMed |
| 41152543 | The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/41152543 | PubMed |
| 40762016 | Neoadjuvant immunotherapy for resectable primary liver cancer (Review). | Oncol Lett | 2025 | https://conductscience.org/library/papers/40762016 | PubMed |
| 40426198 | Nanoparticle-mediated SIRT1 inhibition suppresses M2 macrophage polarization and hepatocarcinogenesis in chronic hepatitis B. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/40426198 | PubMed |
| 40301863 | Clinical correlation and survival analysis of hepatitis B virus infection in oral squamous cell carcinoma: a retrospective study of 1373 patients. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40301863 | PubMed |
| 40160817 | The role of immune regulation in HBV infection and hepatocellular carcinogenesis. | Front Immunol | 2025 | https://conductscience.org/library/papers/40160817 | PubMed |
| 39796705 | Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39796705 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37736699
GET https://conductscience.org/api/papers/v1/37736699/references?page=2